Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study

What Was Tested

Researchers studied Somatostatin and Lanreotide in this clinical trial, phase ii publication.

To test this hypothesis, the researchers conducted a Phase II, non-randomized, open trial investigating lanreotide in MCC patients with advanced disease (ClinicalTrials.gov identifier: NCT02351128).

Why It Was Studied

Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.

The primary endpoint was disease control rate (DCR) (defined as the proportion of patients with complete response, partial response, and stable disease) at 3 months.

Secondary endpoints included progression-free survival (PFS), overall survival (OS), somatostatin receptor (SSTR) tumor expression, and treatment safety.

What Was Measured

PubMed files the paper under topics including Somatostatin, Carcinoma, Merkel Cell, Peptides, Cyclic, Skin Neoplasms, Neoplasm Staging and Receptors, Somatostatin.

Author keywords: Merkel cell carcinoma, dermatology and tumors.

What This Means in Plain Language

This is a phase 2 clinical trial of Somatostatin and Lanreotide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Cancer medicine), a journal based in United States.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.